View Author
patient treatment hepatitis resistance response hepatitis b therapy study baseline level ef ficacy hepatology monotherapy adefovir virus etv monotherapy month follow-up hepatitis b virus hbv dna hbeag ficacy hbv dna levels tenofovir tdf monotherapy virologic response mutation virologic virological analysis virological response entecavir na-na genotypic range tdf treatment breakthrough genotypic resistance serum lamivudine table baseline hbv dna history probability tenofovir disoproxil fumarate week 48 hbv-dna failure combination infection lam resistance adv resistance 48 weeks group na-na ıve patients department na-experienced fication presence treatment failure lam adv hbeag status hepatology 2010 vol lam-resistance virologic breakthrough hbeag-positive lam-resistant mutations signi effect gastroenterology na-na ïve patients adefovir dipivoxil european ftc combination virological breakthrough liver hbsag center subject zoulim
6 Most Recent Publications
|
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
(Article)
Zoutendijk, R. Reijnders, J.G.P. Berg, T. Hansen, B.E. Sonneveld, M.J. Wedemeyer, H. Janssen, H.L.A. Zoulim, F. Brown, A. Mutimer, D.J. Deterding, K. Hofmann, W.P. Petersen, J. Fasano, M. Buti, M. |
2013-05-01
|
|
Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study
(Article)
Si-Ahmed, S.N. Pradat, P. Wedemeyer, H. Janssen, H.L.A. Zoulim, F. Zoutendijk, R. Buti, M. Mallet, V. Cruiziat, C. Deterding, K. Dumortier, J. Bailly, F. Esteban, R. |
2011-10-01
|
|
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
(Article)
Zoutendijk, R. Reijnders, J.G.P. Bömmel, F. van Pradat, P. Oo, Y. Luetgehetmann, M. Berg, T. Hansen, B.E. Wedemeyer, H. Janssen, H.L.A. Brown, A. Zoulim, F. Mutimer, D. Deterding, K. Petersen, J. Hofmann, W.P. Buti, M. Santantonio, T. |
2011-08-01
|
|
Adefovir serum levels do not differ between responders and nonresponders
(Article)
Deterding, K. Naesens, L. Buti, M. Janssen, H.L.A. Kirschner, J. Guerrero, A. Reijnders, J.G.P. Neyts, J. Zoulim, F. Wedemeyer, H. |
2011-07-01
|
|
Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues
(Article)
Reijnders, J.G.P. Deterding, K. Petersen, J. Zoulim, F. Santantonio, T. Buti, M. Bömmel, F. van Hansen, B.E. Wedemeyer, H. Janssen, H.L.A. |
2010-04-01
|
|
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues
(Article)
Bömmel, F. van Man, R.A. de Sarrazin, C. Böcher, W.O. Spengler, U. Wasmuth, H.E. Reinders, J.G.P. Möller, B. Rhode, P. Feucht, H.H. Wiedenmann, B. Berg, T. Wedemeyer, H. Deterding, K. Petersen, J. Buggisch, P. Erhardt, A. Hüppe, D. Stein, K. Trojan, J. |
2010-01-01
|
